Refining clinical trial inclusion criteria to optimize the standardized response mean of the CMTPedS

Kayla M. D. Cornett, Manoj P. Menezes, Paula Bray, Rosemary R. Shy, Isabella Moroni, Emanuela Pagliano, Davide Pareyson, Tim Estilow, Sabrina W. Yum, Trupti Bhandari, Francesco Muntoni, Matilde Laura, Mary M. Reilly, Richard S. Finkel, Katy J. Eichinger, David N. Herrmann, Michael E. Shy, Joshua Burns & CMTPedS Study Group

School of Health Sciences, University of Sydney, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia
Paediatrics and Child Health, University of Sydney, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia
Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, Iowa
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
Department of Occupational Therapy, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Division of Neurology, Perelman School of Medicine, The Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania
UCL Institute of Child Health and National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK
MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK
Translational Neurosciences (Pediatrics), St. Jude Children’s Research Hospital, Memphis, Tennessee
Department of Neurology, University of Rochester, Rochester, New York
Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, Iowa

Correspondence
Kayla M. D. Cornett, The University of Sydney & The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia. Tel: +61 2 9845 3402; E-mail: kayla.cornett@health.nsw.gov.au

Received: 27 June 2020; Accepted: 13 July 2020

doi: 10.1002/acn3.51145

Abstract
The CMT Pediatric Scale (CMTPedS) is a reliable, valid, and responsive clinical outcome measure of disability in children with CMT. The aim of this study was to identify the most responsive patient subset(s), based on the standardized response mean (SRM), to optimize the CMTPedS as a primary outcome measure for upcoming clinical trials. Analysis was based on a 2-year natural history data from 187 children aged 3–20 years with a range of CMT genetic subtypes. Subsets based on age (3–8 years), disability level (CMTPedS score 0–14), and CMT type (CMT1A) increased the SRM of the CMTPedS considerably. Refining the inclusion criteria in clinical trials to younger, mildly affected cases of CMT1A optimizes the responsiveness of the CMTPedS.

Introduction
The CMT Pediatric Scale (CMTPedS) is a reliable, valid, and sensitive clinical outcome measure of disease severity in children and adolescents aged 3–20 years. Recent natural history data shows significant progression over 2 years at a rate of 2.4 ± 4.9 (14%) for all genetic subtypes of CMT (P < 0.001) and 1.8 ± 4.2 (12%) for CMT1A (P < 0.001). Although this rate of progression was significant, due to the slowly progressive nature and phenotypic variability of CMT there is value determining if there are subsets of patients that are more responsive on the CMTPedS to maximize power, and reduce sample size, in clinical trials by refining the inclusion criteria.

Responsiveness is the ability of an outcome measure to detect change over time. The standardized response mean (SRM) is an effect size index used to gauge the responsiveness of outcome measures, calculated by dividing the mean change by the standard deviation of the change. An SRM >0.8 is considered to indicate large responsiveness, 0.5–0.8 moderate, and 0.2–0.5 low. Based on natural history data for all types of CMT, the SRM of the CMTPedS is 0.5 and for patients with CMT type 1A the SRM is 0.4. The aim of this study was to determine the most responsive patient subset(s), based on the SRM, to optimize the CMTPedS as a primary outcome measure for upcoming clinical trials.

Methods
187 participants aged 3–20 years enrolled in the Inherited Neuropathy Consortium were assessed at baseline and
after 2 years using the CMTPedS as previously described (Table 1). Baseline variables were iteratively correlated with CMTPedS change scores to determine the most responsive patient subsets. Baseline variables considered for optimization iterations were age, height, weight, gender, foot deformity, disability level, and CMT genetic subtype. Foot deformity was assessed using the Foot Posture Index. Disability was defined by a CMTPedS score of 0–14 (mild), 15–29 (moderate), and 30–44 (severe).

Statistical analysis

Data were analyzed using SPSS v. 25.0 (IBM Corp. Armonk, NY). All data were assessed for normality and the appropriate parametric or nonparametric test subsequently employed. Bivariate correlations were used to determine potential variables for the optimization. Disease progression and SRM were calculated for patient subgroups of significantly correlated variables. An alpha level of 0.05 was used for statistical significance.

Results

Baseline age, height, weight and disability level were significantly correlated with the CMTPedS change score ($P < 0.05$). Due to high intercorrelations between age, height, and weight ($r > 0.84, P < 0.001$), only age was considered for optimization. The SRM of the CMTPedS increased considerably for several age and disability level subsets (Table 2). In particular, children aged 3–8 years with any type of CMT and a mild level of disability had a SRM of 0.8. For children aged 3–8 years with CMT1A and a mild level of disability, the SRM was 0.9. There were not enough children to evaluate responsiveness within other genetic subtypes such as CMT1B, CMT2A, CMT4C.

Discussion

Refining the inclusion criteria in clinical trials to younger, mildly affected cases of CMT1A would optimize the SRM of the well-validated CMTPedS. As CMT is a progressive disease, intervening at the earliest stages of the disease will be important to halt or modify disease progression. The importance of early intervention has been shown in other progressive neuromuscular conditions such as Spinal Muscular Atrophy where intervening early and even presymptomatically has the best results.

Sample size considerations are important in rare diseases. By determining the most responsive patient subsets, based on the SRM of the CMTPedS, recruitment will be faster and trials will be more economical. For example, for a 2-year randomized (1:1) double-blind, parallel-group, placebo-controlled trial of an intervention aiming to halt the rate of progression would require 24 participants per arm for children aged 3–8 years with mild disability level compared to 66 per arm if inclusion criteria are not refined (Table 2). Note that adjustments would need to be made for correlation between pretest/posttest scores, loss to follow-up, and nonadherence. In CMT1A, the required sample size per arm would be 20 for children aged 3–8 years with mild disability level, whereas 86 per arm would be required if all cases of CMT1A were included.

The CMTPedS is a fit for purpose outcome measure for clinical trials of disease-modifying, rehabilitative and surgical interventions in children and adolescents with CMT. Refining the inclusion criteria to younger, mildly affected cases of CMT1A optimizes the responsiveness of this well-validated clinical outcome measure.

Acknowledgments

DH, FM, JB, ML, MR, MS, RF, and SY acknowledge support from the National Institutes of Neurological Diseases and Stroke and office of Rare Diseases (U54NS065712). The INC (U54NS065712) is a part of the NCATS Rare Diseases Clinical Research Network (RDCRN). MMR is grateful to the Medical Research Council (MRC), MRC Centre grant (G0601943). MMR and ML are grateful to the National Institute for Health Research University College London Hospitals Biomedical Research Centre. FM wishes to acknowledge the support of the MRC Neuromuscular Centre and of the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London and the MDUK Centre grant. JB, DP and IM acknowledge support from ACMT Rete, Charcot-Marie-Tooth Association and Muscular Dystrophy Association.

Conflict of Interest

The authors have no conflicts of interest to disclose.

| Characteristic | Baseline | Follow-up |
|---------------|----------|-----------|
| Age, y        | 9.8 ± 3.9| 11.8 ± 3.8|
| Height, cm    | 1.40 ± 0.22| 1.49 ± 0.20|
| Weight, kg    | 38.1 ± 16.4| 45.2 ± 18.5|
| Foot posture index, 0 to 12 | 1.1 ± 4.3 | 0.5 ± 4.5 |
| CMTPedS, 0 to 44 | 17.3 ± 9.1 | 19.6 ± 9.4 |

Values are mean ± SD.
Author Contributions

KMDC and JB performed study concept and design. KMDC, MPM, RRS, IM, EP, DP, TE, SWY, TB, FM, ML, RSF, KJE, DNH, MES, and JB performed data acquisition and analysis. KMDC, MES, and JB drafted the manuscript and figures.

CMTPedS Study Group: Kayla M. D. Cornett, PhD1, Manoj P. Menezes, PhD2, Rosemary R. Shy, MD3, Daniela Calabrese4, Maria Foscan4, Silvia Genitrini4, Isabella Moroni, MD4, Emanuela Pagliano, MD4, Davide Pareyson, MD4, Timothy Estilow, OTR/L5, Sabrina W. Yum, MD6, Trupti Bhandari, PT7, Francesco Muntoni, MD, FRCPCH7, Matilde Laura, PhD8, Mary M. Reilly, MD, FRCP8, Richard S. Finkel, MD9, Kate J. Eichinger, DPT10, David N. Herrmann, MBBCh10, Paula Bray, PhD1, Michael E. Shy, MD11 and Joshua Burns, PhD1.

References

1. Burns J, Ouvrier R, Estilow T, et al. Validation of the Charcot–Marie–Tooth disease pediatric scale as an outcome measure of disability. Ann Neurol 2012;71:642–652.
2. Cornett KM, Menezes MP, Shy RR, et al. Natural history of Charcot-Marie-Tooth disease during childhood. Ann Neurol 2017;82:353–359.
3. Cornett KM, Menezes MP, Bray P, et al. Phenotypic variability of childhood Charcot-Marie-Tooth disease. JAMA Neurol 2016;73:645–652.
4. Morrow JM, Sinclair CDJ, Fischmann A, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol 2016;15:65–77.
5. Redmond AC, Crosbie J, Ouvrier RA. Development and validation of a novel rating system for scoring standing foot posture: the Foot Posture Index. Clin Biomech 2006;21:89–98.
6. Burns J, Menezes M, Finkel RS, et al. Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2013;18:177–180.
7. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscular Disord. 2019;29:842–856.
8. Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag 2019;15:1153.